Global Renal Denervation Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Symplicity, Enlightn, Vessix, Paradise, Iberis, Others), by Technology (Radiofrequency, Ultrasound, Micro-Infusion), by End User (Hospitals, Specialty Clinics, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Renal Denervation Market Insights Forecasts to 2035

• The Global Renal Denervation Market Size Was Estimated at USD 0.47 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 39.88% from 2025 to 2035
• The Worldwide Renal Denervation Market Size is Expected to Reach USD 18.85 Billion by 2035
• Asia Pacific is Expected to Grow the Fastest during the Forecast Period.

The Global Renal Denervation Market Size was Worth around USD 0.47 Billion in 2024 and is Predicted to Grow to around USD 18.85 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 39.88% from 2025 to 2035. The growing prevalence of hypertension, demand for effective treatment options, and technological advancements with upsurging awareness about the procedure’s benefits are driving the renal denervation market globally.  

Market Overview

The renal denervation market refers to the industry encompassing the products, technologies, and services related to renal denervation procedures, which are minimally invasive treatments for resistant hypertension. Renal denervation is often used where medications alone haven’t been effective, aimed at lowering blood pressure by interrupting nerve signals in the kidneys. The renal denervation market is expanding owing to the changing lifestyle that leads to increasing chances of resistant hypertension and the prevalence of hypertension. Further, the emergence of alternative technologies, including micro-infusion for renal denervation, has been developing, which is propelling the market growth. Unmet medical needs for the treatment of hypertension, increasing awareness, advanced technologies including renal denervation systems, and an increased prevalence rate of resistant hypertension are several factors that are escalating the market for renal denervation. The increasing prevalence of chronic diseases and obesity is driving the need for renal denervation therapy, thereby escalating the market opportunities. Further, an advancement in new techniques in these healthful routines for enhancing results is driving the market growth for renal denervation.

Report Coverage

This research report categorizes the renal denervation market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the renal denervation market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the renal denervation market.

Driving Factors

The growing prevalence of hypertension, which is a leading risk for cardiovascular morbidity and mortality, is driving the renal denervation market. As per WHO, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. Renal denervation, including catheter-based renal denervation, has been shown to lower blood pressure in sham-controlled trials, representing a device-based, complementary treatment option for hypertension. Further, the increasing use of renal denervation due to several benefits, including lower blood pressure, reducing the risk of cardiovascular events, and improving kidney function, significantly contributes to market growth.

Restraining Factors

The high regulatory standards and negative reimbursements associated with these devices are challenging the renal denervation market. The increased price of renal denervation devices discourages their uptake due to funding constraints, which are restraining the market growth. Further, the inconsistent clinical trial outcomes of these devices may lead to hindering the market growth.

Market Segmentation

The renal denervation market share is classified into product type, technology, and end user.

• The symplicity segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the product type, the renal denervation market is divided into symplicity, enlightn, vessix, paradise, iberis, others. Among these, the symplicity segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The frequent use of simplicity renal denervation for hypertension treatment, due to its delivery of low-level radiofrequency energy and consequent reduction in the risk of radiation exposure to body tissues, is responsible for driving the market.

• The radiofrequency segment dominated the market with a major market share in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the technology, the renal denervation market is divided into radiofrequency, ultrasound, micro-infusion. Among these, the radiofrequency segment dominated the market with a major market share in 2024 and is projected to grow at a substantial CAGR during the forecast period. The technology uses heat energy to selectively damage or destroy nerves around the renal arteries to reduce nerve activity that aids in lowering blood pressure. The benefits of radiofrequency renal denervation, including its safety and time efficiency, are responsible for driving the market growth.

• The hospitals segment dominated the renal denervation market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the renal denervation market is divided into hospitals, specialty clinics, and others. Among these, the hospitals segment dominated the renal denervation market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Renal denervation is potentially used in hospitals for treating resistant hypertension as a multi-prolonged approach. The presence of advanced infrastructure and access to special personnel in the hospitals segment is responsible for driving market growth.

Regional Segment Analysis of the Renal Denervation Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the renal denervation market over the predicted timeframe.

North America is anticipated to hold the largest share of the renal denervation market over the predicted timeframe. The increased prevalence of hypertension, especially resistant hypertension, along with the growing adoption of innovative technologies, is driving the renal denervation market in the region. Further, the development of novel technologies for renal denervation systems, including micro-infusion, is propelling the market growth.

Asia Pacific is expected to grow at a rapid CAGR in the renal denervation market during the forecast period. The growing unmet medical requirements associated with hypertension treatment and technological advancements are propelling the market. The presence of key market players including Boston Scientific, Medtronic, and ReCor Medical in the region significantly contributes to propelling the market for renal denervation.

Europe is anticipated to hold a significant share of the renal denervation market during the projected timeframe. The use of renal denervation procedures for the management of hypertension, with its significant benefits, efficacy, and safety, is responsible for driving the regional market. Further, the high healthcare expenditure, along with the rising burden of cardiovascular diseases and metabolic disorders, is contributing to driving the market for renal denervation.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the renal denervation market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Medtronic
• Abbott
• Ablative Solutions, Inc
• Mercator MedSystems, Inc.
• Otsuka Medical Devices Co., Ltd.
• Boston Scientific Corporation
• SympleSurgical, Inc.
• Johnson & Johnson Services, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In January 2025, Medtronic plc, a global leader in healthcare technology, announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation.
• In November 2023, Medtronic received approval from the Food & Drug Administration for its Simplicity Spyral renal denervation device, the second device of its kind to be authorized by the agency.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the renal denervation market based on the below-mentioned segments: 

Global Renal Denervation Market, By Product Type

• Symplicity
• Enlightn
• Vessix
• Paradise
• Iberis
• Others

Global Renal Denervation Market, By Technology

• Radiofrequency
• Ultrasound
• Micro-Infusion

Global Renal Denervation Market, By End User

• Hospitals
• Specialty Clinics
• Others

Global Renal Denervation Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa